Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.» Read More
LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover bid from Pfizer in May, now expects revenue to grow in low...
LONDON, Nov 6- AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue to grow slightly this...
Global pain will mean U.S. gain at least in terms of stock market investing, according to a strongly bullish analysis from Mario Gabelli's team.
Some of Monday's midday movers:
Shares of Bristol-Myers hit a 13-year high on Thursday. So why was one big trader getting bearish?
Even after a big move from the Fed, "Mad Money" host Jim Cramer thinks there are some apologies owed to investors.
Oct 30- A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood thinner for use in some patients with atrial fibrillation. According to late-stage trial data submitted by Daiichi, the drug is as effective- and safer than- warfarin, an anticoagulant that has been on the market for more...
Jim Cramer announces his best-of-breed stock picks. Those that will always circle back, because success is a part of their DNA.
Some of Thursday's midday movers:
Oct 28- U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for some atrial fibrillation patients, but suggested limiting its use to those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein that plays a central role in...
Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...
Some of the names on the move ahead of the open.
Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, fueled by strong sales of its treatments for blood clots, cancer and arthritis. That compared with $692 million, or 42 cents per share, in the year-earlier period. Revenue fell 4 percent to $3.92 billion, largely due to the company's earlier divestiture of diabetes products,...
Stocks head into Friday on track for the best weekly performance in 22 months, yet new Ebola fears and other geopolitical headlines could be wild cards.
Jim Cramer said next week is the most important week of the year for earnings. Find out what stocks he will be focused on.
Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention
Some of Tuesday's midday movers:
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
Upset by the spiral lower? Cramer feels your pain. And he’s developed strategies for surviving circumstances just like these.
You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?